ClinicalTrials.gg

Program

lumacaftor

Also written as “LUM/IVA”, “Lumacaftor” and “VX-809”.

Its studies are mostly in Cystic Fibrosis · Cognitive Dysfunction, led by 3 companies.

Furthest: phase 4, since Aug 15, 201623 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals210 open or runningphase 4since Aug 15, 2016Mar 18, 2009none ahead
Qanatpharma11 open or runningphase 2since May 5, 2025May 5, 2025May 2027phase 2 · NCT07695090
Qanatpharma Canada10 open or runningphase 1since Jul 21, 2023Jul 21, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Mar 18, 2009.

  1. Jul 8, 2013Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT01897233 · 62 enrolled · United States, Canada
  2. Jul 10, 20132 phase 1 studies in Cystic FibrosisVertex Pharmaceuticals · NCT01899105, NCT01910415
  3. Aug 26, 2013Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT01931839 · 1,164 enrolled · United States, Australia, Austria and more
  4. Mar 11, 2015Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT02390219 · 46 enrolled · United States
  5. Jul 23, 2015Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT02514473 · 206 enrolled · United States, Australia, Belgium and more
  6. Sep 1, 2015Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT02544451 · 246 enrolled · United States, Australia, Belgium and more
  7. Aug 15, 2016Phase 4 study in Cystic FibrosisVertex Pharmaceuticals · NCT02875366 · 70 enrolled · Australia, United Kingdom
  8. Feb 9, 2017Phase 2 study in Cystic FibrosisVertex Pharmaceuticals · NCT03061331 · 20 enrolled · Netherlands
  9. Apr 19, 2017Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT03125395 · 57 enrolled · United States, Canada
  10. Jul 18, 2018Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT03601637 · 61 enrolled · United States, Canada
  11. Aug 7, 2018Phase 2 study in Cystic FibrosisVertex Pharmaceuticals · NCT03625466 · 51 enrolled · Germany
  12. Jan 15, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04235140 · 52 enrolled · United States, Canada
  13. Jul 21, 2023Qanatpharma Canada's first study: phase 1 study in Healthy VolunteerNew to Qanatpharma CanadaQanatpharma Canada · NCT05968612 · 39 enrolled · Canada
  14. May 5, 2025Qanatpharma's first study: phase 2 study in Cognitive DysfunctionNew to QanatpharmaQanatpharma · NCT07695090 · 60 planned · Canada

Ahead

  1. May 2027Primary completion: phase 2 study in Cognitive DysfunctionQanatpharma · NCT07695090

TargetBeta

CFTR →read by rule
“Cystic fibrosis transmembrane conductance regulator stabiliser”ChEMBL 37, by rule

Other programs on CFTR

ProgramCompanyFurthest phaseStudies
ivacaftorruleVertex Pharmaceuticalsphase 478
tezacaftorruleVertex Pharmaceuticalsphase 339

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07695090Cognitive Dysfunction · Canada2RecruitingQanatpharmaMay 202760
NCT05968612Healthy Volunteer · Canada1CompletedQanatpharma CanadaDec 18, 202339
NCT04235140Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsAug 22, 202352
NCT03625466Cystic Fibrosis · Germany2CompletedVertex PharmaceuticalsOct 9, 202051
NCT03601637Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsOct 29, 202161
NCT03125395Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsJul 17, 201957
NCT03061331Cystic Fibrosis · Netherlands2CompletedVertex PharmaceuticalsSep 6, 201720
NCT02875366Cystic Fibrosis · Australia, United Kingdom4CompletedVertex PharmaceuticalsSep 201770
NCT02544451Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsAug 2018246
NCT02514473Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsSep 2016206
NCT02390219Cystic Fibrosis · United States3CompletedVertex PharmaceuticalsOct 201646
NCT01931839Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsApr 20161,164
NCT01910415Cystic Fibrosis · Netherlands1CompletedVertex PharmaceuticalsMar 2014200
NCT01899105Cystic Fibrosis · United States1CompletedVertex PharmaceuticalsAug 201328
NCT01897233Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsOct 201562
NCT01888393Hepatic Impairment · Czech Republic, Slovakia1CompletedVertex PharmaceuticalsNov 201323
NCT01807949Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsApr 2014563
NCT01807923Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsApr 2014559
NCT01768663Cystic Fibrosis · United States1CompletedVertex PharmaceuticalsSep 201380
NCT01225211Cystic Fibrosis · United States, Australia, Belgium and more2CompletedVertex PharmaceuticalsApr 2014312
NCT01216046Cystic Fibrosis · United States1CompletedVertex PharmaceuticalsMay 201148
NCT00966602Cystic Fibrosis · Netherlands1CompletedVertex PharmaceuticalsDec 200924
NCT00865904Cystic Fibrosis · United States, Belgium, Canada and more2CompletedVertex PharmaceuticalsDec 200993

How it is read

Names in the registry

  • “LUM/IVA”, 8 entries
  • “Lumacaftor”, 5 entries
  • “VX-809”, 4 entries
  • “Lumacaftor Plus Ivacaftor Combination”, 3 entries
  • “Lumacaftor 200 MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.